A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Pharmacogenetics (London)

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00008571-200201000-00001PMID 11773858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

  2004cited by this paper
• The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.

  2002cited by this paper
• A Single Nucleotide Polymorphic Mutation in the Human μ-Opioid Receptor Severely Impairs Receptor Signaling*

  2001cited by this paper
• Regulation of μ-Opioid Receptor Gene Transcription by Interleukin-4 and Influence of an Allelic Variation within a STAT6 Transcription Factor Binding Site*

  2001cited by this paper
• Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence.

  2001cited by this paper
• Incomplete cross tolerance and multiple mu opioid peptide receptors.

  2001cited by this paper
• Allelic Variation S268P of the Human μ-Opioid Receptor Affects Both Desensitization and G Protein Coupling

  2000cited by this paper
• Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence.

  2000cited by this paper
• Opioid receptor and peptide gene polymorphisms: potential implications for addictions.

  2000cited by this paper
• Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

  1998cited by this paper
• Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine.

  1997cited by this paper

• An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine

  2016cites this paper
• Epigenetic Modeling and Stem Cells in Toxicology Testing

  2014cites this paper
• Genotype Variability and Haplotype Profile of Abcb1 (Mdr1) Gene Polymorphisms in Macedonian Population

  2014cites this paper
• The Metabolism of Antiparasitic Drugs and Pharmacogenetics in African Populations: From Molecular Mechanisms to Clinical Applications

  2013cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Mood and Withdrawal Symptoms in Relation to Plasma Concentrations of Methadone in Patients Undergoing Methadone Maintenance Treatment

  2012cites this paper
• Increased clearance of morphine in sickle cell disease: implications for pain management.

  2011cites this paper
• Tolerance and Withdrawal From Prolonged Opioid Use in Critically Ill Children

  2010cites this paper
• Strong opioids in cancer pain : clinical and pharmacogenetic factors influencing an individual's response to morphine and oxycodone

  2010cites this paper
• Chapter 24 – Leukotrienes and Lipoxins

  2009cites this paper
• The influence of opioids on gastric function: experimental and clinical studies

  2008cites this paper
• Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.

  2008cites this paper
• Pharmacogenetics of morphine: Potential implications in sickle cell disease

  2008cites this paper
• Variable response to opioid treatment: any genetic predictors within sight?

  2008cites this paper
• In-Office Laryngeal Surgery with the 585nm Pulsed Dye Laser (PDL)

  2007cites this paper
• NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients.

  2007cites this paper
• Pharmacogenetic aspects of addictive behaviors

  2007cites this paper
• Suchttherapeutika zur Sucht

  2006cites this paper
• Polymorphisms in the DBH and DRD2 gene regions and smoking behavior

  2006cites this paper
• A simple nonparametric multipoint procedure to test for linkage through mothers or fathers as well as imprinting effects in the presence of linkage

  2005cites this paper
• Morphine 6beta glucuronide: fortuitous morphine metabolite or preferred peripheral regulatory opiate?

  2005cites this paper
• Contribution to variability in response to opioids

  2005cites this paper
• Analgesia and local anesthesia during invasive procedures in the neonate.

  2005cites this paper
• Morphine more fine? Its effects in critically ill newborns

  2004cites this paper
• Polyspecific organic cation transporters: their functions and interactions with drugs.

  2004cites this paper
• Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia.

  2004cites this paper
• Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European‐Americans

  2003cites this paper
• Polymorphic CYP2A6 and its clinical and toxicological significance

  2003cites this paper
• Pharmacogenomics: marshalling the human genome to individualise drug therapy

  2003cites this paper